Beiersdorf's Derma Division Outshines as Core Brands Drag Shares to Decade Low

The German skincare and consumer goods group Beiersdorf finds itself at a crossroads, with a resilient medical skincare unit providing the only bright spot in an otherwise bleak first-quarter report. Shares in the DAX-listed company have slumped to levels not seen in ten years, touching a fresh 52-week low of 69.92 euros — extending a decline that has wiped nearly 42% off the stock over the past twelve months. The rout accelerated after the Hamburg-based group posted a 7.7% drop in nominal revenues to 2.48 billion euros for the first quarter, underscoring troubles that run far deeper than mere market sentiment.

Derma surges while Nivea and La Prairie stumble

The consumer segment bore the brunt of the headwinds. Nivea, Beiersdorf's flagship brand, suffered a 7.0% organic decline in sales, while the luxury Swiss label La Prairie saw its organic revenues tumble 14.9%. Management attributed La Prairie's slump to disruptions in the US department-store channel and Chinese travel retail, though it noted that adjusted for these temporary effects, the brand's underlying retail sales actually rose 9%. The weakness was not isolated to consumer products: the industrial adhesives division Tesa posted an organic drop of 4.3%, partly due to a tough comparison base in electronics.

Against this gloom, the Derma unit — home to Eucerin and Aquaphor — delivered organic growth of 8.2%. The division saw explosive gains in China, where revenues jumped 87%, and in Brazil, where sales more than doubled. North American Derma sales expanded 7.0%. The company has now positioned this segment as its primary growth engine, betting it can offset sluggishness elsewhere.

Should investors sell immediately? Or is it worth buying Beiersdorf?

Shares hit fresh lows despite buyback efforts

The sell-off in Beiersdorf's stock has been relentless. After touching 70.22 euros earlier in the week, the shares slid further to 69.92 euros, marking the lowest point since 2015. Since the start of 2026, the stock has lost roughly 25%, and the distance to its 200-day moving average has widened to more than 22%. A share buyback programme launched for the 2026/2027 period has done little to stem the bleeding: between 6 and 8 May alone, the company repurchased 34,800 of its own shares, yet the downward trend remained intact.

Management stands by full-year forecast

Beiersdorf at a turning point? This analysis reveals what investors need to know now.

Chief executive Vincent Warnery characterised the first quarter as an outlier, pointing to an unusually high comparison base, temporary channel disruptions, and delayed innovation effects that he expects will not recur. The company reaffirmed its 2026 guidance, calling for flat to modest organic sales growth in the consumer business and an operating EBIT margin slightly below the prior year's level. The outlook hinges on a recovery at Nivea and La Prairie in the second quarter, as well as sustained momentum in the Derma division.

Investors remain unconvinced. Without a visible turnaround in the core consumer brands, the stock lacks a clear fundamental catalyst to put in a durable floor. The Derma unit's strong performance, while encouraging, has yet to compensate fully for the erosion elsewhere in the portfolio.

Ad

Beiersdorf Stock: New Analysis - 14 May

Fresh Beiersdorf information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Beiersdorf analysis...

en | DE0005200000 | BEIERSDORFS | boerse | 69328989 |